SRR13780262
— · cohortSC
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortSC
- subtype
- cohortSC
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.210
- FATTY_ACID_METABOLISM+0.200
- PANCREAS_BETA_CELLS+0.200
- PEROXISOME+0.190
- BILE_ACID_METABOLISM+0.180
- SPERMATOGENESIS+0.180
- CHOLESTEROL_HOMEOSTASIS+0.160
- KRAS_SIGNALING_DN+0.140
- MITOTIC_SPINDLE+0.140
- ANGIOGENESIS+0.120
Top 10 suppressed
- ALLOGRAFT_REJECTION-0.470
- INTERFERON_ALPHA_RESPONSE-0.460
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.460
- IL6_JAK_STAT3_SIGNALING-0.450
- INTERFERON_GAMMA_RESPONSE-0.440
- TNFA_SIGNALING_VIA_NFKB-0.410
- INFLAMMATORY_RESPONSE-0.390
- COMPLEMENT-0.350
- NOTCH_SIGNALING-0.330
- TGF_BETA_SIGNALING-0.310
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | ERR2208929 | — | — | 0.826 |
| 2 | R360 | — | — | 0.809 |
| 3 | SRR8518274 | — | C | 0.804 |
| 4 | R55 | — | — | 0.801 |
| 5 | SRR1516068 | — | — | 0.801 |
| 6 | SRR23303758 | — | — | 0.797 |
| 7 | 4ca7e773-3858-4ece-b78a-c576b20a5cf3 | — | — | 0.790 |
| 8 | SRR12202497 | — | — | 0.790 |
| 9 | SRR1516065 | — | — | 0.788 |
| 10 | TCGA-4Z-AA7R-01A-11R-A39I-07 | — | — | 0.785 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 21 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.210 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.200 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.200 | Cobimetinib | — uncovered |
| PEROXISOME | 0.190 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.180 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.180 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.160 | Remibrutinib | — uncovered |
| KRAS_SIGNALING_DN | 0.140 | Remibrutinib | — uncovered |
| MITOTIC_SPINDLE | 0.140 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.120 | Remibrutinib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.120 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.110 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.110 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.100 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.090 | Remibrutinib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.060 | Remibrutinib | — uncovered |
| ANDROGEN_RESPONSE | 0.050 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.050 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.040 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.020 | Idelalisib | — uncovered |